Poseida Sinks On Prostate Cancer CAR-T Clinical Hold
The Newly Public Company’s Stock Closed Down 30%
Executive Summary
Poseida’s technologies are designed to deliver safer, more effective cell and gene therapies, but the first trial for its autologous PSMA-targeting CAR-T therapy was put on a clinical hold after a patient died.
You may also be interested in...
Second Cellectis CAR-T Therapy On Clinical Hold, Dosing Could Be Issue
A Phase I study for allogeneic therapy UCARTCS1A was put on clinical hold after a patient died. High dosing and double exposure to cyclophosphamide pre-conditioning may have played a role.
IPO Update: High-Flying Biopharma IPOs Average 77.1% Return Through Q2
The performance of 29 biopharma firms that launched IPOs during the first half of 2020 is staggering compared with 28 drug developers that went public in the first half of 2019 with a 10% average return.
ASCO 2020: BCMA CAR-T Race Heats Up Between Bristol And Janssen
The gap between potential approvals for Bristol’s ide-cel and Janssen’s JNJ-4528 has narrowed as both CAR-T therapies show high response rates in multiple myeloma – and as bispecific antibodies, including Janssen’s teclistamab, edge into the space.